The optimization of the diagnostic work-up in patients with suspected obstructive lung disease

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Visser, Frank J ^a   van der Vegt, Milena J M M ^a   van der Wilt, Gert J ^b   Janssen, Julius P ^a  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; HISTAMINE; PREDNISONE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PROSPECTIVE STUDY; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UTILIZATION REVIEW;

ASTHMA; COST-BENEFIT ANALYSIS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SINGLE-BLIND METHOD;

EID: 78549242686     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-60     Document Type: Article

References (10)

1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
2. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995, 8:1398-1420. 10.1183/09031936.95.08081398, 7489808.
3. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention (updated 2005). 2006, Ref Type: Internet Communication, Global Initiative for Asthma (GINA).
4. Quanjer P, Tammeling GJ. Standardized lung function testing. Official statement of the ERS. Eur Respir J 1993, 6:5-40.
5. Cockcroft DW. Bronchoprovocation methods: direct challenges. Clin Rev Allergy Immunol 1994, 24:19-26.
6. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968. 10.1183/09031936.05.00035205, 16264058.
7. Commissie diagnostiek astma bronchiale en COPD N Standaard diagnostiek van astma bronchiale en COPD. Pulmoscript 1994, 1994:31-46. Commissie diagnostiek astma bronchiale en COPD N.
8. Dales RE, Suissa S. Clinical interpretation of airway response to a bronchodilator: epidemiologic considerations. Am Rev Respir Dis 1988, 138:317-320.
9. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Maual for costing studies. Methods and standard cost prices for economic evaluations in health care. National Health Insurance Board (in Dutch) 2004,
10. Lung function testing: selection of reference values and interpretative strategies:oficial statement ATS. Am Rev Respir Dis 1991, 144:1202-1216.